Sign In
Buy OVID
$2.62
-0.0100 (-0.380%)
At Close: Aug 10, 2026
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
11:01am, Wednesday, 05'th Aug 2026
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID
03:45am, Wednesday, 29'th Jul 2026
Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID
03:45am, Wednesday, 29'th Jul 2026
ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
07:00am, Wednesday, 08'th Jul 2026
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
09:03pm, Tuesday, 07'th Jul 2026
Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions
04:20pm, Tuesday, 07'th Jul 2026
Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacol
Ovid Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
07:00am, Wednesday, 03'rd Jun 2026
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
07:00am, Tuesday, 12'th May 2026
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safet
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
08:36am, Monday, 27'th Apr 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participan
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
06:41pm, Tuesday, 14'th Apr 2026
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
08:00am, Wednesday, 08'th Apr 2026
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages
02:50am, Thursday, 26'th Mar 2026
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports.
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
07:45am, Friday, 20'th Mar 2026
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity see
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
05:02pm, Wednesday, 18'th Mar 2026
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
